Welcome to our dedicated page for Align Technology news (Ticker: ALGN), a resource for investors and traders seeking the latest updates and insights on Align Technology stock.
Align Technology reports developments in digital orthodontics and restorative dentistry through its Invisalign System of clear aligners, iTero intraoral scanners, exocad CAD/CAM software and the Align Digital Platform. Company news commonly covers product and workflow updates for clear-aligner treatment planning, intraoral scanning, 3D visualization and digitally connected dental practices.
Recurring updates also include quarterly and annual operating results, clear-aligner shipment and channel trends, regional demand, foreign-exchange effects, stock repurchase activity, financial-conference participation and governance or shareholder-voting matters. Other announcements describe clinical education, professional collaborations and access-to-care initiatives involving orthodontists, general practitioner dentists and dental research organizations.
Align Technology (Nasdaq: ALGN) announced a $200.0 million open‑market repurchase of common stock under its existing $1.0 billion buyback program approved April 2025. Repurchases will use a Rule 10b5-1 trading plan, be funded with cash on hand, and are expected to complete by October 2026.
As of March 31, 2026, Align reported 71.6 million shares outstanding and $1,059.8 million in cash and cash equivalents, including $206.6 million held domestically allocated to support the repurchases.
Align Technology (Nasdaq: ALGN) previewed mid-2026 product innovations at AAO 2026, showcasing Invisalign Specifix™ 3D printed attachments, Invisalign integrated buttons, and an Invisalign Palatal Expander with integrated hooks, plus iTero Lumina™ scanner and ClinCheck® platform enhancements to extend digital treatment planning, 3D printing, and connected workflows.
The release highlights independent clinical validation showing the Invisalign Palatal Expander produced bone and bite changes comparable to a traditional Hyrax expander and details limited-market custom trimline options.
Align Technology (NASDAQ: ALGN) reported Q1'26 revenue of $1,040.1M, up 6.2% year-over-year and down 0.7% sequentially. Record Clear Aligner shipments reached 685,650 cases, up 6.7% year-over-year. GAAP diluted EPS was $1.57; non-GAAP diluted EPS was $2.58. The company completed a $200M repurchase plan and expects to repurchase an additional $200M beginning on or about May 1, 2026. Management reaffirmed full-year 2026 revenue growth guidance of +3% to +4% and reiterated targets for operating margins, capex, and volume growth.
Align Technology (Nasdaq: ALGN) was named a Top 100 Global Innovator in the LexisNexis Innovation Momentum 2026 report for the fifth consecutive year, earning a “Five‑Year Top 100 Global Innovator” distinction.
Align cites a global portfolio of more than 3,000 active patents and patent applications, ~295.6 thousand doctor customers, and innovation across AI treatment planning, direct 3D printing, digital diagnostics, and ortho‑restorative design.
Align Technology (Nasdaq: ALGN) will report first quarter 2026 results on April 29, 2026 after market close. Financial results will be released at 4:00 p.m. ET and the company will host a conference call at 4:30 p.m. ET with a live audio webcast.
The webcast will be available on the Investor Relations site, participants may pre-register, and an archived audio webcast will be posted two hours after the call and remain available for one month. Align cites ~295.6k doctor customers, a 600 million consumer market opportunity, and ~22.1 million patients treated over 29 years.
Align Technology (Nasdaq: ALGN) will present at two financial conferences in Miami on March 10–11, 2026. Presentations are scheduled at the Leerink Partners Global Healthcare Conference on March 10 at 9:20–9:50 a.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30–8:55 a.m. ET.
Speakers include John Morici, EVP Global Finance and CFO, and Madelyn Valente, Director Corporate Communications Investor Relations. Both presentations will be webcast live via the company investor relations website, with archived replays available for about one month.
Align Technology (Nasdaq: ALGN) reported Q4'25 record total revenue of $1,047.6M, up 5.2% sequentially and 5.3% year-over-year, and record Q4 clear aligner shipments of 676.9K cases. FY2025 revenue was a record $4.035B, clear aligner revenue $3.245B, and clear aligner shipments 2.611M.
Q4 GAAP net income was $135.8M ($1.89 diluted EPS); non-GAAP net income was $236.0M ($3.29 diluted EPS). Company repurchased 2.9M shares in 2025 and expects 2026 revenue growth of 3%–4%.
Align Technology (NASDAQ: ALGN) is collaborating with the University of Bern on Switzerland’s first large-scale Swiss Oral Health Study, launched August 2025. The study will scan approximately 1,800 children by June 2026 and 1,650 adults by end-2027 across six cantons.
Align is supplying the iTero Lumina intraoral scanner and an Align-branded mobile dental van to enable on-site digital scans, NIRI imaging and longitudinal data collection to improve diagnostic accuracy and public-health planning.
Align Technology (NASDAQ: ALGN) announced on January 13, 2026 that it will sponsor 30 Invisalign treatments through the Canadian Foundation for the Advancement of Orthodontics (CFAO) Smiles4Canada program to help children and teens with significant orthodontic needs whose families lack financial resources.
The company said the support builds on its global charitable programs, noting Smiles4Canada has helped more than 800 children to date and Align’s ARK program has waived lab fees for over 200 patients since 2019. Align highlighted discounted-fee and donation programs across Canada, the US, EMEA and Australia to expand access to Invisalign care.
Align Technology (Nasdaq: ALGN) will report Q4 and full-year 2025 results on Wednesday, February 4, 2026 after market close. Financial results will be released at 4:00 p.m. ET and a conference call will follow at 4:30 p.m. ET, available via live audio webcast on the company Investor Relations site. An archived webcast will be posted about two hours after the call and remain available for one month.
Align also published anticipated 2026 quarterly earnings dates (Q1'26 Apr 29; Q2'26 Jul 29; Q3'26 Oct 28; Q4'26 Feb 3, 2027) and reiterated operating scope: ~291.0 thousand doctor customers, ~21.4 million patients treated, and a 600 million consumer market opportunity.